DXRX Stock Overview
A diagnostic commercialisation company, provides data, data analytics, and implementation services for pharmaceutical companies worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for DXRX from our risk checks.
Diaceutics PLC Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£1.33 |
| 52 Week High | UK£1.35 |
| 52 Week Low | UK£0.82 |
| Beta | 0.46 |
| 1 Month Change | 35.20% |
| 3 Month Change | 38.02% |
| 1 Year Change | 45.60% |
| 3 Year Change | 3.11% |
| 5 Year Change | 50.57% |
| Change since IPO | 38.74% |
Recent News & Updates
Diaceutics PLC (LON:DXRX) Stock Rockets 29% But Many Are Still Ignoring The Company
May 30
Diaceutics PLC's (LON:DXRX) Subdued P/S Might Signal An Opportunity
Jan 31Recent updates
Diaceutics PLC (LON:DXRX) Stock Rockets 29% But Many Are Still Ignoring The Company
May 30Diaceutics PLC's (LON:DXRX) Subdued P/S Might Signal An Opportunity
Jan 31Industry Analysts Just Made A Notable Upgrade To Their Diaceutics PLC (LON:DXRX) Revenue Forecasts
Jan 28Estimating The Intrinsic Value Of Diaceutics PLC (LON:DXRX)
Jul 24Would Shareholders Who Purchased Diaceutics' (LON:DXRX) Stock Year Be Happy With The Share price Today?
Feb 04
Here's Why We Don't Think Diaceutics's (LON:DXRX) Statutory Earnings Reflect Its Underlying Earnings Potential
Dec 31Do Insiders Own Lots Of Shares In Diaceutics PLC (LON:DXRX)?
Nov 27Shareholder Returns
| DXRX | GB Life Sciences | GB Market | |
|---|---|---|---|
| 7D | 3.9% | -1.1% | -0.6% |
| 1Y | 45.6% | -46.1% | 6.4% |
Return vs Industry: DXRX exceeded the UK Life Sciences industry which returned -45.7% over the past year.
Return vs Market: DXRX exceeded the UK Market which returned 6.3% over the past year.
Price Volatility
| DXRX volatility | |
|---|---|
| DXRX Average Weekly Movement | 3.9% |
| Life Sciences Industry Average Movement | 7.1% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in GB Market | 11.2% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: DXRX's share price has been volatile over the past 3 months.
Volatility Over Time: DXRX's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 151 | Ryan Keeling | www.diaceutics.com |
Diaceutics PLC, a diagnostic commercialisation company, provides data, data analytics, and implementation services for pharmaceutical companies worldwide. The company offers DXRX – The Diagnostic Network, a diagnostic commercialisation platform for precision medicine that integrates pipelines of diagnostic testing data from network of laboratories. It also provides DXRX data solutions, including DXRX Signal, allows customer to engage with a physician whilst making treatment decisions, therefore maximizing brand sales and marketing; DXRX Physician Mapping, examines physician testing behavior using patient level data to determine testing rates, methodology, and the physician to lab relationship; DXRX Lab Mapping which offers insights into labs currently testing patients diagnosed with a specific disease or biomarker; and DXRX Disease Testing Rate Tracker which delivers biomarker testing rate reports showing biomarker testing rates per indication.
Diaceutics PLC Fundamentals Summary
| DXRX fundamental statistics | |
|---|---|
| Market cap | UK£111.87m |
| Earnings (TTM) | -UK£1.75m |
| Revenue (TTM) | UK£23.70m |
4.7x
P/S Ratio-64.1x
P/E RatioIs DXRX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DXRX income statement (TTM) | |
|---|---|
| Revenue | UK£23.70m |
| Cost of Revenue | UK£3.99m |
| Gross Profit | UK£19.71m |
| Other Expenses | UK£21.45m |
| Earnings | -UK£1.75m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.021 |
| Gross Margin | 83.15% |
| Net Profit Margin | -7.37% |
| Debt/Equity Ratio | 0% |
How did DXRX perform over the long term?
See historical performance and comparison